Search

Men with advanced germ cell tumors (GCT) treated with chemotherapy are at high risk of venous thromboembolism (VTE). Predictors of VTE may identify patients who would benefit from prophylactic anticoagulation. Men with advanced GCT (Stage IS, II, III) treated with chemotherapy were identified at 2 centers. High genomic risk was defined from a 5 single nucleotide polymorphism (SNP) germline panel. Logistic regression was used to evaluate the impact of genomic risk on VTE within 6 months of chemotherapy initiation. Orthogonal Projection to Latent Structures Discriminant Analysis (OPLS-DA) was used to build models to predict VTE based on clinical variables and an 86 SNP panel. This 123-patient cohort experienced a VTE rate of 26% with an incidence of high genomic risk of 21%. Men with high genomic risk did not have a significantly higher VTE rate (31%, 8/26) than men with low genomic risk (25%, 24/97), unadjusted OR 1.4 (95% CI 0.5-3.5, P =.54). Incorporation of clinical variables (Khorana score, N3 status and elevated LDH) resulted in adjusted OR 2.1 (95% CI 0.7-6.5, P =.18). A combined model using clinical variables and 86 SNPs performed similarly (AUC 0.77) compared to clinical variables alone (AUC 0.72). A previously established 5-SNP panel was not associated with VTE among patients with GCT receiving chemotherapy. However, multivariable models based on clinical variables alone warrant further validation to inform prophylactic anticoagulation strategies. VTE occurs at a high rate in men with germ cell tumors treated with curative intent chemotherapy. A 5-SNP genetic risk panel was not significantly associated with VTE in a retrospective cohort of 123 patients. Clinical variables alone with or without a broad 86 SNP panel did successfully identify a high-risk population who warrant further study of prophylactic anticoagulation. [ABSTRACT FROM AUTHOR]

Background: Aggressive large B‐cell lymphomas (LBCLs) are curable, but previous studies have shown inferior outcomes in minorities. Nurse navigation programs can improve patient outcomes by providing patient support. This study presents the outcomes of White and minority patients with aggressive LBCL at an institution with an active nurse navigation program. Methods: The authors prospectively collected baseline characteristics, treatment regimens, and outcome data for patients with aggressive LBCL. Navigation encounters were characterized as low or high intensity. Overall survival (OS) and progression‐free survival (PFS) were calculated with Kaplan‐Meier methods. Baseline characteristics were compared with Fisher exact tests. Results: Two hundred four consecutive patients (47 minority patients and 157 White patients) were included. Results were presented as minorities versus Whites. There were no differences in prognostic scores (Revised International Prognostic Index score of 3‐5, 43% vs 47%; P =.50), frontline chemotherapy (98% vs 96%; P =.68), or the incidence of relapsed/refractory disease (40% vs 38%; P =.74). For relapsed/refractory LBCL, similar proportions of patients underwent hematopoietic stem cell transplantation (32% vs 29%; P >.99) or chimeric antigen receptor T‐cell therapy (16% vs 19%; P >.99). Enrollment in clinical trials was comparable (17% vs 14%; P =.64). More than 85% received nurse navigation, but minorities had higher intensity navigation encounters (42% vs 21%; P =.01). The 2‐year OS rates were 81% and 76% for minorities and Whites, respectively (P =.27); the 2‐year PFS rates were 62% and 65%, respectively (P =.78). Conclusions: This study shows similar survival between Whites and minorities with aggressive LBCL, which was likely due to equal access to guideline‐concordant therapy. Minorities received higher intensity navigation encounters, which may have helped them to overcome socioeconomic disadvantages. Although other studies have shown worse outcomes for minorities with aggressive large B‐cell lymphoma, this study demonstrates similar survival in White and minority patients. The authors attribute the equitable outcomes to equal access to guideline‐conforming care and novel treatment options, which may have been attainable by overcoming barriers via the aid of nurse navigation. [ABSTRACT FROM AUTHOR]